52 results about "Intestinal metaplasia" patented technology

Devices and methods are provided for ablating areas of the gastrointestinal tract affected with certain benign, pre-cancerous, or early cancerous lesions that originate within the epithelium and are limited to the mucosal layer of the gastrointestinal tract wall. Examples of such lesions include benign conditions such as cervical inlet patch (ectopic gastric mucosa in the upper esophagus), as well as pre-cancerous and cancerous conditions such as intestinal metaplasia/intra-epithelial neoplasia/early cancer of the stomach, squamous intra-epithelial neoplasia and early cancer of the esophagus, oral and pharyngeal leukoplakia, flat colonic polyps, anal intra-epithelial neoplasia (AIN), and early cancers of the anal canal. Ablation, as provided the invention, commences at the epithelial layer of the gastrointestinal wall and penetrates deeper into the gastrointestinal wall in a controlled manner to achieve a successful patient outcome, the latter of which is defined generally as eradication of the targeted lesion, and/or a change in the targeted lesion to prevent or forestall patient morbidity. Embodiments of the device include an ablational electrode array that spans 360 degrees and an array that spans an arc of less than 360 degrees.

The invention provides a medicine composition for treating chronic atrophic gastritis, which has the advantages of obvious curative effect and convenient carrying. The medicine composition can not only improve various clinical symptoms of the chronic atrophic gastritis, but also improve intestinal metaplasia and heterotypic hyperplasia accompanying the chronic atrophic gastritis, thereby realizing stomach cancer prevention by the medicine. The medicine composition is prepared by the extracts of roasted milkvetch root, radix codonopsis pilosulae, dried orange peel, nutagrass flatsedge rhizome, white peony root, Chinese yam, black plum and liquorice; the preparation process is simple and is suitable for mass production; the clinical tests show that the preparation 'stomach nourishing granules' prepared by the technical proposal can fully improve various symptoms of the chronic atrophic gastritis, achieve the aim of clinical curing, and has more stable efficacies in particular to the chronic atrophic gastritis caused by weakness of the spleen and the stomach or weakness of the spleen and the stomach and qi stasis.

The invention relates to a novel purpose of dendrobium candidum, which aims at providing an application of the dendrobium candidum to the preparation of medicine for treating intestinal metaplasia. The invention discloses the application of the dendrobium candidum to the preparation of the medicine for treating the intestinal metaplasia and a preparation method of the medicine for treating the intestinal metaplasia on the basis of the dendrobium candidum. Both dendrobium candidum particles provided by the invention and Yangweishu particles have a certain reversing effect on the intestinal metaplasia caused by N- methyl-N'-nitryl-N-nitrosoguanidine (MNNG), but the effect of the dendrobium candidum particles is more obvious. Results show that the dendrobium candidum particles mixed with American ginseng has the potential application prospects on the intestinal metaplasia of clinic chronic atrophic castritis (CAG).

The invention provides a gastric mucosa calibration solution. A stock solution of medical India ink and sterile water for injection are prepared into fixed concentrations respectively, prepared solutions are black suspensoid solutions from the appearance, are uniform, and have no cakes or precipitation, the pH value is neutral, and the carbon content is 0.60 percent. The gastric mucosa calibration solution is prepared by the following steps: the stock solution of the India ink is shaken up and then is diluted by the sterile water for injection in a sterile environment according to volume ratios; and the prepared solutions are put into small glass bottles and are subject to moist heat sterilization by an arnold steam method at the temperature of 100 DEG C for 30 minutes. As a calibration solution retained for a longer time after being injected into inside a living body, the gastric mucosa calibration solution can mark for a longer time, is safe, has no toxic side effect, and meets the national standard; the gastric mucosa calibration solution can be retained after the return visit date, and fully meet the requirement of follow-up biopsy sampling of a gastroscope; and the gastric mucosa calibration solution does not interfere and affect the observation of tissue pathologies, does not affect the recognition of cellular morphology and precancerous pathological changes such as mucosal layer morphology, intestinal metaplasia and so on, and does not affect the judgment to normal tissue morphologies.

The invention belongs to the field of traditional Chinese medicines, and particularly relates a traditional Chinese medicine preparation for treating chronic gastritis and a method for preparing the traditional Chinese medicine preparation. The traditional Chinese medicine preparation comprises active components including rhizoma cyperi, Chinese thorowax roots, parched white peony roots, fructus aurantii immaturus, raw licorice, poria cocos, cortex magnoliae officinalis, dried tangerine or orange peel, roasted rhizoma atractylodis macrocephalae, roasted atractylodes lancea, codonopsis pilosula, allium macrostemon, curcuma aromatica, armeniaca mume, barbary wolfberry fruits and long pepper according to certain weights. Pharmaceutical conventional excipients can be added into a composition, namely the traditional Chinese medicine preparation, according to conventional pharmaceutical processes to obtain pharmaceutically acceptable oral preparations. The traditional Chinese medicine preparation and the method have the advantages that effects of soothing livers, harmonizing stomachs, conditioning qi movement and repairing gastric mucosae can realized by the traditional Chinese medicine preparation which is a traditional Chinese medicine, and special curative effects can be realized by the traditional Chinese medicine preparation for treating chronic superficial gastritis, ulcerative gastritis, atrophic gastritis, bile reflux gastritis, intestinal metaplasia gastritis, gastritis with other complications and helicobacter pylori positive gastritis; the clinically practiced traditional Chinese medicine preparation is reliable in efficacy, and recurrence can be prevented after patients are cured; as clinically applied, the total effective rate reaches 98.5%, and the traditional Chinese medicine preparation is free of adverse reaction and is safe and reliable.

The invention discloses a traditional Chinese medicine composition for treating chronic atrophic gastritis. The composition adopts the following 18 components for compatibility: largehead atractylodes rhizome, orange fruit, nutgrass galingale rhizome, dangshen, coptis root, medicinal evodia fruit, almonds, sharpleaf galangal fruit, radix astragali, turmeric root tuber, medicated leaven, raw hawthorn, morinda root, weeping forsythia capsule, radix bupleuri, honeysuckle, akebia stem and white paeony root. The composition has obvious treatment effects on chronic gastritis, intestinal metaplasia accompanied by atrophic gastritis and atypical hyperplasia. The composition has the following pharmacological characteristics that the composition invigorates the spleen and supplements qi, harmonizes the liver and spleen, regulates qi and dissipates dampness, removes stasis to stop pains, softens hardness to break stones, nourishes and relaxes the liver, nourishes yin with sour and sweet herbs and can adjust the functions of pylorus, prevent backflow of bile and promote damaged tissue healing and gastric mucosa regeneration. The composition makes up for the deficiency of single traditional Chinese medicine preparations, solves the problems that the Western medicines fail to solve and toxic and side effects and has short course of treatment and low side effects.

The invention discloses a Shenzhu pharmaceutical composition for treating atrophic gastritis. The pharmaceutical composition comprises the following raw materials in parts by weight: 10-20 parts of codonopsis pilosula, 8-12 parts of largehead atractylodes rhizome, 8-12 parts of baical skullcap root, 13-17 parts of danshen root, 25-35 parts of coix seed, 8-12 parts of hairyvein agrimonia herb and bud, 12-18 parts of spreading hedyotis herb, 13-17 parts of barbed skullcap herb, 13-17 parts of Mongolian dandelion herb, 8-12 parts of Chinese waxgourd semen, 8-12 parts of curcuma zedoary and 9-11 parts of bitter orange. The invention also discloses an application of the Shenzhu pharmaceutical composition for treating atrophic gastritis in preparation of medicines for treating atrophic gastritis, intestinal metaplasia and atypical hyperplasia. The Shenzhu pharmaceutical composition disclosed by the invention has the effects of replenishing qi to invigorate the spleen, removing heat and dampness, and detoxifying and activating blood circulation, can reverse and prevent gastric mucosa carcinogenesis, and can be used for treating atrophic gastritis, intestinal metaplasia and atypical hyperplasia which are caused by weakness of spleen and stomach and damp-heat syndromes.

The invention discloses a traditional Chinese medicine formula for treating a chronic gastric disease, aiming at solving the problems that a plurality of types of gastric diseases exist and have diversity and complexity, the Western medicine takes a temporary solution and cannot completely treat the gastric disease, existing Chinese patent medicines cannot completely meet the diversity and complexity treatment characteristics of the gastric disease so that a lot of patients cannot be healed after a long period and the gastric disease repeatedly breaks out. The traditional Chinese medicine formula is prepared from rhizoma corydalis, wrinkled giant hyssop, costus roots, Chinese thorowax roots, adenophora stricta, pinellia ternata, white atractylodes rhizomes, coix seeds, bitter oranges, mangnolia officinalis, fructus amomi and the like. The traditional Chinese medicine formula has a very good effect on treating the gastric disease and has a very good curative effect on the plurality of types of gastric diseases (including stomachache, indigestion, stomach distension, acute and chronic gastroenteritis, superficial gastritis, atrophic gastritis, erosive gastritis, gastric ulcer and enterelcosis, gastric and intestinal metaplasia and the like); the difficulties that the gastric disease cannot be healed after a long period and repeatedly breaks out are completely overcome; the traditional Chinese medicine formula has the characteristics of rapid effect, good curative effect, complete treatment and uneasiness of breaking out, and is deeply favored by a lot of patients.

Medications for the prevention and treatment of the progression of gastroesophageal reflux disease to adenocarcinoma, and more specifically to medications that operate in accordance with a new mechanistic understanding of the sequence of changes whereby gastroesophageal reflux disease progresses to adenocarcinoma are provided. The medications for the prevention and treatment of reflux-induced adenocarcinoma are based on (1) recognizing cardiac mucosa as an abnormal epithelium that should be a target of treatment, (2) preventing cardiac mucosa from progressing to intestinal metaplasia (Barrett esophagus), and (3) promoting the conversion of cardiac mucosa to oxyntocardiac mucosa, which is recognized by the invention as being a benign epithelium that does not progress to intestinal metaplasia (Barrett esophagus) and adenocarcinoma. In patients who already have intestinal metaplasia at the time of detection, the medications for prevention and treatment require a preliminary step whereby the intestinal metaplasia is reverted to cardiac mucosa before it can be induced to convert to the benign oxyntocardiac mucosa.

The invention discloses application of a Chinese medicinal composition to treatment of stomach chronic inflammation with intestinal metaplasia and intraepithelial neoplasia. The Chinese medicinal composition mainly comprises a plurality of traditional Chinese medicines such as vietnamese sophora root, bistort rhizome, dahurian patrinia herb, root bark of shaggy-fruited dittany, common selfheal fruit-spike, airpotato yam rhizome and the like.

An oral medicine for treating gastrosis and enteropathy, including gastrorrhagia, gastric ulcer, gastritis, chronic enteritis, colitis, etc contains charred rabbit hide (10-20 pts.wt.), charred ox hide (30-40 pts.wt.), charred sheep hide (30-40 pts.wt.), charred dog hide (10-20 pts.wt.) and charred donkey hide (5-10 pts.wt.). Its advantages are high curative effect, low toxic by-effect, and low recurrence rate.

The invention discloses a traditional Chinese medicine composition for treating intestinal metaplasia and a preparation method thereof. The traditional Chinese medicine composition comprises active ingredients: 30-80 parts by weight of hedyotis diffusa, 8-15 parts by weight of rhizoma curcumae, 20-30 parts by weight of raw coix seed and 25-35 parts by weight of salvia chinensis. The traditional Chinese medicine composition for treating intestinal metaplasia as gastric precancerous lesion and adopting the four drugs for intestinal metaplasia has a scientific ratio, and the components can coordinate and promote each other and produce a synergistic effect. The traditional Chinese medicine believes that the traditional Chinese medicine pathogenesis of intestinal metaplasia as gastric precancerous lesion can be summarized as spleen and stomach weakness, and damp heat and blood stasis combination. The traditional Chinese medicine treatment utilizes the principle of strengthening body resistance and eliminating evil. The traditional Chinese medicine composition has effects of clearing away heat, removing toxins and resolving dampness, and promoting blood circulation, removing blood stasisand eliminating stagnation, simplifies the formula, accurately utilizes drugs, has a precise formula, can reverse the precancerous lesions of the gastric cancer, has a definite clinical effect, is easy to take, has good patient tolerance and prevents untoward effects in long term use. The traditional Chinese medicine preparation can promote standardized treatment with traditional Chinese medicines.

The invention discloses a construction method and application of a spontaneous gastric precancerous lesion animal model, and relates to the technical field of medical treatment. The gene knockout heterozygous animal ATP4a < +/-> is constructed, and the gene knockout heterozygous animal ATP4a < +/-> is used as the gastric precancerous lesion animal model, can spontaneously generate gastric mucosa full-thickness tissue heterotypic incomplete intestinal epithelial metaplasia lesion, can be used as the gastric precancerous lesion animal model, and can be used as a gastric precancerous lesion animal model. The compound is suitable for research and development of gastric precancerous lesion pathogenesis and efficacy and mechanism of new drugs for resisting chronic atrophic gastritis.

The invention discloses a traditional Chinese medicine Niweikang, which comprises hemsleya amabilis, Lungwortlike lobaria herb, radix astragali, airpotato yam rhizome, herba scutellariae barbatae and endoconcha sepiae. The traditional Chinese medicine is utilized to treat precancerous lesions of gastric cancer, such as superficial gastritis, chronic atrophic gastritis with intestinal metaplasia, atypical hyperplasia and the like and has the advantages of treating both principal and secondary aspect of disease, strengthening body resistance and eliminating evil, being remarkable in efficacy, high in cure rate, free of toxic and side effects, not easy to have a relapse, no drug injury and drug resistance and low in cost and improving immunity of the organism and the like.

The invention discloses a traditional Chinese medicine composition for treating precancerous lesion chronic atrophic gastritis and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 8 to 12 parts of herba eupatorii, 3 to 8 parts of Pu-Erh tea, 8 to 12 parts of rhizoma corydalis, 5 to 10 parts of faeces trogopterori (stir-fried with vinegar), 10 to 15 parts of jasminum grandiflorum, 3 to 8 parts of amomum tsao-ko and 3 to 8 parts of liquorice root. The traditional Chinese medicine composition disclosed by the invention can obviously improve clinical symptoms of chronic atrophic gastritis, reverse intestinal metaplasia or atypical hyperplasia lesions, and reduce the incidence of the gastric cancer caused by chronic atrophic gastritis.